Akero Therapeutics Net Income

As of the most recent data (September 2025), AKRO shows a net income of $-290M. That compares with $-240M in the prior-year period — down 23.4% year over year. That is below the Healthcare sector average of $16B. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, AKRO's net income is now $-290M (was $-240M) — a 23.4% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether Akero Therapeutics is outperforming or lagging.

The Healthcare sector average net income is about $16B. Akero Therapeutics is at $-290M, which is lower that average. That is roughly 101.8% below the sector mean. Use the comparison chart on this page to see how AKRO stacks up against individual peers as well.

Tracking AKRO's net income over time shows whether Akero Therapeutics is scaling, shrinking, or reshaping that part of the business. The current reading is $-290M That compares with $-240M in the prior-year period — down 23.4% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this net income page, Stockcircle has Akero Therapeutics's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect net income (currently $-290M) with ownership activity and broader fundamentals.